Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 21

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 21
---
                | (156,200 | ) |
| Total shareholders’ equity                                                                                 |     | $              |   56,325 |   |
| Total capitalization                                                                                       |     | $              |   71,162 |   |

| (1) | Excludes the impact of ordinary shares that are issuable upon                                                                                  
 the exercise of outstanding warrants, including the IR/PR Warrants. Further, as all of the ordinary shares offered by the Selling Shareholders 
 pursuant to this prospectus will be sold by the Selling Shareholders for their respective accounts, we will not receive any of the proceeds    
 from such sale; however, we expect to receive approximately $12.26 million from the exercise of the IR/PR Warrants, assuming such IR/PR        
 Warrants were exercised in full, unless such IR/PR Warrants were exercised on a “cashless” basis, which proceeds are not                       
 reflected in the table above.                                                                                                                  |

<div align='center'>8

USE OF PROCEEDS</div>

All
of the ordinary shares offered by the Selling Shareholders pursuant to this prospectus will be sold by the Selling Shareholders for their
respective accounts. We will not receive any of the proceeds from these sales. All net proceeds from the sale of the ordinary shares covered
by this prospectus will go to the Selling Shareholders; however, we expect to receive approximately $12.26 million from the exercise of
the IR/PR Warrants, assuming such IR/PR Warrants were exercised in full, unless such IR/PR Warrants were exercised on a “cashless”
basis.

<div align='center'>9

DESCRIPTION OF THE SECURITIES</div>

The
material terms and provisions of our ordinary shares are described under the caption “Description of Securities” that served
as Exhibit 2.1 to our Annual Report.

<div align='center'>10

SELLING SHAREHOLDERS</div>

This
prospectus relates to the possible resale by the Selling Shareholders of up to 3,463,202 ordinary shares by the Selling Shareholders.

The
Selling Shareholders may from time to time offer and sell any or all of the ordinary shares set forth below pursuant to this prospectus.
In this prospectus, the term “Selling Shareholders” includes (i) the entities identified in the table below (as such
table may be amended from time to time by means of an amendment to the registration statement of which this prospectus forms a part